Larimar Therapeutics
LRMR
85 hedge funds and large institutions have $78.5M invested in Larimar Therapeutics in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 21 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.6% less ownership
Funds ownership: 7% → 6.4% (-0.6%)
10% less funds holding
Funds holding: 94 → 85 (-9)
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
49% less capital invested
Capital invested by funds: $153M → $78.5M (-$74.7M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $100K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.63M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$2.01M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.11M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$942K |
| 5 |
Renaissance Technologies
New York
|
+$871K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$3.71M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.52M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.39M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.71M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.59M |
LRMR Hedge Fund Activity: Q1 2019 in Review
85 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2019, worth a combined $78.5M — down 49% from $153M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of LRMR and 12 opened new positions — a net loss of 9 holders — while 24 trimmed existing stakes and 30 added.
The largest buyer was Armistice Capital, adding an estimated $3.63M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $3.71M sold.
- 85 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2019, down from 94 in Q4 2018.
- Funds reported $78.5M of Larimar Therapeutics stock for Q1 2019, down 49% quarter-over-quarter.
- 12 funds opened new Larimar Therapeutics positions in Q1 2019 and 21 closed out, a net change of -9 holders.
- The largest Larimar Therapeutics buyer in Q1 2019 was Armistice Capital, an estimated $3.63M added.
- The largest Larimar Therapeutics seller in Q1 2019 was Ghost Tree Capital, an estimated $3.71M sold.
Based on aggregated 13F filings for Q1 2019.